CymaBay Therapeutics, Inc. (CBAY) Financials

CBAY Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 434.7 million 142.4 million
2023-09-30 451.0 million 124.9 million
2023-06-30 226.7 million 118.2 million
2023-03-31 245.3 million 141.1 million

CBAY Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -27.6 million 4.7 million
2023-09-30 -26.1 million 3.7 million
2023-06-30 -25.5 million 3.4 million
2023-03-31 6.2 million 3.5 million

CBAY Net Income

No data available :(

CBAY Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 394.3 million - 5.3 million
2023-09-30 438.8 million - 206000
2023-06-30 213.8 million - 374000
2023-03-31 236.4 million - 537000

CBAY Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 113.3 million
2023-09-30 105.7 million
2023-06-30 102.2 million
2023-03-31 98.0 million

CBAY Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 180000 22.7 million 19.8 million -
2023-09-30 - 20.0 million 12.2 million -
2023-06-30 70000 19.5 million 11.6 million -
2023-03-31 195000 18.6 million 8.3 million -

CBAY Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 57000 56000
2023-09-30 - 215000
2023-06-30 31.0 million 211000
2023-03-31 - 199000

CBAY

Price: $32.48

52 week price:
7.26
32.50

Earnings Per Share: -0.93 USD

P/E Ratio: -34.58

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 528000

Ebitda: -8.0 million

Market Capitalization: 3.7 billion

Links: